Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
40.91
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
Dell To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
January 03, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
December 29, 2023
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion...
Via
Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...
Via
Benzinga
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
December 18, 2023
GSK plc (NYSE: GSK)
Via
Benzinga
Looking Into GSK's Recent Short Interest
December 18, 2023
Via
Benzinga
Price Over Earnings Overview: GSK
November 22, 2023
Via
Benzinga
Looking Into GSK's Recent Short Interest
November 20, 2023
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth
December 22, 2023
GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks.
Via
InvestorPlace
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
December 21, 2023
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...
Via
Benzinga
Exposures
Product Safety
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n
Via
Benzinga
Exposures
COVID-19
Why Is Genetic Medicines-Focused Wave Life Sciences Stock Trading Lower Today?
December 07, 2023
Wave Life Sciences Ltd (NASDAQ: WVE) has priced its previously announced underwritten public offering of 20 million shares at $5.00 per share with approximately
Via
Benzinga
Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market
November 30, 2023
Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billio
Via
Benzinga
3 Stocks to Sell for Tax Losses Before the New Year
November 28, 2023
While no one wants to lose in the market, you can be productive with the red ink through stocks to sell for tax losses.
Via
InvestorPlace
3 Great Foreign Companies to Invest in Right Now
November 27, 2023
The world is a big place, and many great companies are based outside our U.S. borders.
Via
The Motley Fool
GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data
November 27, 2023
GSK plc (NYSE: GSK) announced headline
Via
Benzinga
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
November 18, 2023
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, Inc.'s (NYSE:
Via
Benzinga
Exposures
Product Safety
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
November 17, 2023
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump.
Via
Benzinga
Diversifying Your Portfolio With Plant-Based Options
November 16, 2023
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...
Via
Talk Markets
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
November 16, 2023
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over...
Via
Benzinga
Current Analysis: GSK Plc
November 16, 2023
In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales.
Via
Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
November 15, 2023
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
November 13, 2023
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi
Via
Benzinga
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
November 08, 2023
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth
Via
InvestorPlace
3 Healthcare Stocks Getting Help From the Aging Population
November 06, 2023
America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions.
Via
InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
November 02, 2023
Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns.
Via
InvestorPlace
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
November 02, 2023
The company issued below-consensus sales views for 2023 and 2024.
Via
Investor's Business Daily
GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch
November 01, 2023
The company is rivaling Pfizer, which also gained approval this year for an RSV vaccine.
Via
Investor's Business Daily
GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
November 01, 2023
GSK plc (NYSE: GSK) reported Q3 FY23 s
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.